Search all CCR Clinical Trials
Below is a list of all open NCI Center for Cancer Research (CCR) clinical trials, including studies that are currently recruiting patients (i.e. Open - Recruiting) as well as trials that will be recruiting soon (i.e., Open - Not yet Recruiting). Most recently opened trials are listed first.
All CCR clinical trials take place at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.
Clinical trials at the NIH Clinical Center are open to patients with cancer, HIV, or immunodeficiency disorders, regardless of where they live in the United States.
-
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-00-0-251Investigator James L. Gulley, M.D., Ph.D. -
A Phase II study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK cells plus Pembrolizumab plus N-803 for Subjects with Recurrent/Metastatic Gastric or Head and Neck Cancer
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-00-0-096Investigator Jason M. Redman, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-21-C-0012Investigator Andrew M. Blakely, M.D. -
A Phase I/II Study of Sacituzumab Govitecan plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-00-0-144Investigator Anish Thomas, MBBS, M.D. -
Phase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant Mesothelioma
Open - Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-00-0-059Investigator Raffit Hassan, M.D. -
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients with Relapsed/Refractory Hairy Cell Leukemia and Variant
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-21-C-0019Investigator Robert J. Kreitman, M.D. -
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-21-C-0017Investigator Peter A. Pinto, M.D. -
A Phase I/II Trial of Lurbinectedin with Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-00-0-176Investigator Anish Thomas, MBBS, M.D. -
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-21-C-0015Investigator Mark R. Gilbert, M.D. -
A Natural History Study of Children and Adults with Olfactory Neuroblastoma
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0009Investigator Charalampos Floudas, MD, DMSc, MS -
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR-105) for the Treatment of Patients with Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant
Open - Not yet RecruitingNCI Protocol ID NCI-00-0-021Investigator Jennifer A. Kanakry, M.D. -
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0014Investigator Christopher J. Melani, M.D. -
A Phase I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical Neurofibromas
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0011Investigator Andrea M. Gross, M.D. -
A Phase I Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis
Open - RecruitingNCI Protocol ID NCI-21-C-0013Investigator Scott M. Norberg, D.O. -
A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer
Open - Not yet RecruitingNCI Protocol ID NCI-00-0-048Investigator William L. Dahut, M.D. -
Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in patients with advanced cancer
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0007Investigator Houssein Abdul Sater, M.D. -
Close Assessment and Testing for Chronic Graft-vs-Host Disease (CATCH Study)
Open - RecruitingNCI Protocol ID NCI-20-C-0167Investigator Steven Z. Pavletic, M.D., M.S. -
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Selection and Disease Progression in Patients Undergoing Active Surveillance for Prostate Cancer
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0164Investigator Peter A. Pinto, M.D. -
Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0006Investigator Jonathan M. Hernandez, M.D. -
A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0169Investigator Milos Miljković, M.D., M.Sc.